TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01988493
Drug: Tepotinib 500 mg
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study: NCT01988493
Drug: Tepotinib 1000 mg
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal
Study: NCT01988493
Drug: Tepotinib
Normalized name: Tepotinib
DrugBank: Tepotinib (DB15133)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study: NCT01988493
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or participant withdrawal.
Study: NCT02866370
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
Study: NCT02866370
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days\* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.
Study: NCT02866370
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.
Study: NCT02866370
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity.
Study: NCT02093468
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01249690
Drug: Bortezomib,Pirarubicin,Dexamethasone
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
Study: NCT04272255
Drug: scopolamine HBr
Normalized name: SCOPOLAMINE HBR 0.4MG TAB
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal Gel
Study: NCT04272255
Drug: Transdermal Scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patch
Study: NCT01333475
Drug: MK-2206 + AZD6244
Normalized name: vitamin MK 7
DrugBank: MK-2206 (DB16828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
Study: NCT00489190
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00241501
Drug: Esomeprazole (Nexium)
Normalized name: esomeprazole Injection [Nexium]
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03671590
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Daily Dose
Study: NCT00294931
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00294931
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00294931
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00126880
Drug: 3TC
Normalized name: 3TC
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3TC, 150mg BID
Study: NCT02199327
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
Study: NCT02199327
Drug: Interferon Alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
Study: NCT02726308
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg I.V. Dexamethasone just before induction
Study: NCT00475423
Drug: rituximab [MabThera/Rituxan]
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000mg iv on days 1 and 15
Study: NCT03207438
Drug: Quetiapine 50 MG Extended Release Oral Tablet
Normalized name: quetiapine 50 MG Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OD
Study: NCT03207438
Drug: Quetiapine Fumarate XR 150-300 mg
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose ranged from 150 to 300mg, XR preparation, OD
Study: NCT03252600
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03252600
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06228911
Drug: steroid (triamcinolone)
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: triamcinolone is a synthetic corticosteroid medication used topically to treat various skin conditions, to relieve the discomfort of mouth sores, and by injection into joints to treat various joint conditions
Study: NCT00088036
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04049227
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04049227
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01820624
Drug: lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04745273
Drug: Ondansetron 4 MG (Kemoset 4mg)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 4mg (iv) will administer to participants
Study: NCT01023477
Drug: Chloroquine Standard Dose (500mg/week)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Study: NCT01023477
Drug: Chloroquine Low Dose (250mg/week)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
Study: NCT04401800
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules administered orally once daily
Study: NCT01944839
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01944839
Drug: E10030 sham intravitreal injection
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pressure on the eye with a syringe with no needle
Study: NCT00724022
Drug: Basiliximab, Tacrolimus, MMF, Prednisolon
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Control group. Therapy with Prednisolon.
Study: NCT00724022
Drug: Basiliximab, Tacrolimus, MMF
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: No Prednisolon after 7 days
Study: NCT00724022
Drug: Tacrolimus, MMF, rATG
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induction therapy: rATG instead of Basiliximab. No Prednisolon.
Study: NCT04401800
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg intravenous (IV) infusion administered on Day 1 of each cycle
Study: NCT03367572
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT03367572
Drug: Netupitant/Palonosetron Hydrochloride
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03367572
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03367572
Drug: Prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01162135
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.~It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose.
Study: NCT02601469
Drug: DSXS
Normalized name: Dexamethasone sodium succinate
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: twice daily for 28 days
Study: NCT00607971
Drug: Renzapride
Normalized name: Renzapride
DrugBank: Renzapride (DB04917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
Study: NCT00969917
Drug: IPI-504
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
Study: NCT00924170
Drug: LMB-2
Normalized name: LMB-100
DrugBank: LMB-100 (DB18591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
Study: NCT00924170
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-3:~Patients 1-7, 10-14, and \>18:25mg/m\^2/day Patients 8 - 9:30 mg/m\^2/day Patients 15- 17:20 mg/m\^2/day
Study: NCT02598570
Drug: duvelisib
Normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Duvelisib will be administered orally as a fixed dose in 28-day cycles.
Study: NCT02025556
Drug: LBR-101 High Dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously Administered High Dose LBR-101 Monthly x 3
Study: NCT02025556
Drug: LBR-101 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneously Administered Low Dose LBR-101 Monthly x 3
Study: NCT03656536
Drug: Pemigatinib
Normalized name: Pemigatinib
DrugBank: Pemigatinib (DB15102)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
Study: NCT03656536
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
Study: NCT03656536
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m\^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.
Study: NCT02813785
Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
Study: NCT02813785
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be administered as 75 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 21-day cycle.
Study: NCT02362646
Drug: Control Solution
Normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02675829
Drug: ado-trastuzumab emtansine
Normalized name: Ado-Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
Study: NCT02620163
Drug: telmisartan/amlodipine 40/5mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02620163
Drug: telmisartan/amlodipine 80/5mg
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02620163
Drug: telmisartan/amlodipine 40/5mg placebo
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02620163
Drug: telmisartan/amlodipine 80/5mg placebo
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00394992
Drug: Oxaliplatin+capecitabine+bevacizumab
Normalized name: Capecitabine
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
Study: NCT03906916
Drug: Micafungin
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients hospitalised in Internal Medicine with suspicion of invasive candidiasis will be treated with an echinocandin (micafungin) as timely as possible, and they will continue the antifungal treatment according to international guidelines when diagnosis is confirmed by positive 1,3-β-D-glucan test.
Study: NCT00400803
Drug: Gemcitabine, Carboplatin, Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
Study: NCT02282826
Drug: acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT01961583
Drug: 18F-Fluciclatide
Normalized name: fluciclovine (18F)
DrugBank: Fluciclatide (DB14842)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).~Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy
Study: NCT02048241
Drug: Intuniv
Normalized name: Intuniv
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly administration of medication in doses as per protocol
Study: NCT00129909
Drug: fixed dose combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00045721
Drug: O6-benzylguanine
Normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00045721
Drug: polifeprosan 20 with carmustine implant
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03357939
Drug: HLX03
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
Study: NCT03357939
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
Study: NCT00510965
Drug: Intravitreal injection ranibizumab
Normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
Study: NCT02420782
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02420782
Drug: Pilocarpine
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02420782
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral
Study: NCT03869268
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
Study: NCT03869268
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
Study: NCT02618356
Drug: Raltitrexed and S-1
Normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.~BSA (body surface area) S-1 dosage \<1.25 m2 80 mg/d~* 1.25m2 - \<1.5 m2 100 mg/d~* 1.5 m2 120 mg/d
Study: NCT01325220
Drug: arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg bid
Study: NCT01325220
Drug: arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bid
Study: NCT01325220
Drug: arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tid
Study: NCT04065165
Drug: Telotristat Ethyl
Normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250 mg TID orally
Study: NCT04065165
Drug: Lanreotide
Normalized name: Lanreotide
DrugBank: Lanreotide (DB06791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
Study: NCT04531631
Drug: Dorzagliatin
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT00042029
Drug: MK0869, aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02694718
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
Study: NCT03705273
Drug: Dexamethasone IV for PO
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Common pediatric emergency department practice
Study: NCT03705273
Drug: Dexamethasone crushed tablets
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alternative route of administration for patients unable to swallow tablet whole
Study: NCT01551940
Drug: Botox injection
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
Study: NCT00830076
Drug: sitagliptin phosphate
Normalized name: Sitagliptin Phosphate
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
Study: NCT00830076
Drug: metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.